Legal & General Group Plc lifted its stake in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 7.4% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 25,477 shares of the biopharmaceutical company’s stock after buying an additional 1,747 shares during the quarter. Legal & General Group Plc’s holdings in Immunomedics were worth $222,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Perceptive Advisors LLC acquired a new stake in shares of Immunomedics during the 1st quarter worth about $1,941,000. Rhumbline Advisers lifted its stake in shares of Immunomedics by 11.1% during the 2nd quarter. Rhumbline Advisers now owns 123,491 shares of the biopharmaceutical company’s stock worth $1,090,000 after buying an additional 12,375 shares during the last quarter. TD Asset Management Inc. lifted its stake in shares of Immunomedics by 13.8% during the 2nd quarter. TD Asset Management Inc. now owns 150,400 shares of the biopharmaceutical company’s stock worth $1,328,000 after buying an additional 18,200 shares during the last quarter. Creative Planning lifted its stake in shares of Immunomedics by 1.7% during the 2nd quarter. Creative Planning now owns 179,130 shares of the biopharmaceutical company’s stock worth $1,582,000 after buying an additional 3,065 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Immunomedics by 177.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 417,079 shares of the biopharmaceutical company’s stock worth $2,699,000 after buying an additional 266,953 shares during the last quarter. Institutional investors own 57.36% of the company’s stock.
In other Immunomedics news, Director Cynthia L. Goldenberg sold 40,000 shares of the stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $9.24, for a total transaction of $369,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David M. Goldenberg sold 20,000 shares of the stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $12.64, for a total transaction of $252,800.00. The disclosure for this sale can be found here. Insiders have sold 100,000 shares of company stock valued at $1,051,200 in the last quarter. Company insiders own 6.60% of the company’s stock.
IMMU has been the subject of a number of research reports. Jefferies Group LLC raised their target price on shares of Immunomedics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday. BidaskClub upgraded shares of Immunomedics from a “hold” rating to a “buy” rating in a research note on Wednesday, August 23rd. Zacks Investment Research upgraded shares of Immunomedics from a “sell” rating to a “buy” rating and set a $9.50 target price for the company in a research note on Tuesday, July 11th. Finally, Cowen and Company restated an “outperform” rating and set a $15.00 target price on shares of Immunomedics in a research note on Monday, July 24th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Immunomedics has a consensus rating of “Buy” and an average price target of $15.33.
Shares of Immunomedics, Inc. (IMMU) opened at 11.77 on Thursday. The firm has a 50-day moving average of $12.05 and a 200 day moving average of $8.67. Immunomedics, Inc. has a 52 week low of $2.02 and a 52 week high of $14.48. The firm’s market cap is $1.31 billion.
Immunomedics (NASDAQ:IMMU) last issued its earnings results on Wednesday, August 16th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.13). The business had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $0.75 million. The firm’s revenue for the quarter was down 31.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.17) EPS. Equities research analysts predict that Immunomedics, Inc. will post ($0.53) EPS for the current fiscal year.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.